NASDAQ:DCPH Deciphera Pharmaceuticals - DCPH Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Deciphera Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $16.58 -0.13 (-0.78%) (As of 02/7/2023 12:00 AM ET) Add Compare Share Share Today's Range$16.15▼$17.1650-Day Range$14.85▼$22.1052-Week Range$6.51▼$22.76Volume704,075 shsAverage Volume1.06 million shsMarket Capitalization$1.12 billionP/E RatioN/ADividend YieldN/APrice Target$22.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Deciphera Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.56 Rating ScoreUpside/Downside34.0% Upside$22.22 Price TargetShort InterestHealthy9.98% of Float Sold ShortDividend StrengthN/ASustainability-1.55Upright™ Environmental ScoreNews Sentiment0.67Based on 9 Articles This WeekInsider TradingAcquiring Shares$30 M Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.49) to ($2.32) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.83 out of 5 starsMedical Sector30th out of 1,029 stocksPharmaceutical Preparations Industry12th out of 504 stocks 4.3 Analyst's Opinion Consensus RatingDeciphera Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.56, and is based on 6 buy ratings, 2 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $22.22, Deciphera Pharmaceuticals has a forecasted upside of 34.0% from its current price of $16.58.Amount of Analyst CoverageDeciphera Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted9.98% of the float of Deciphera Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverDeciphera Pharmaceuticals has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Deciphera Pharmaceuticals has recently decreased by 33.70%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldDeciphera Pharmaceuticals does not currently pay a dividend.Dividend GrowthDeciphera Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreDeciphera Pharmaceuticals has received a 59.12% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer", "Ripretinib", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Deciphera Pharmaceuticals is -1.55. Previous Next 3.7 News and Social Media Coverage News SentimentDeciphera Pharmaceuticals has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Deciphera Pharmaceuticals this week, compared to 1 article on an average week.Search Interest15 people have searched for DCPH on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat Follows7 people have added Deciphera Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Deciphera Pharmaceuticals insiders have bought 58,677.41% more of their company's stock than they have sold. Specifically, they have bought $29,999,988.00 in company stock and sold $51,040.00 in company stock.Percentage Held by InsidersOnly 4.30% of the stock of Deciphera Pharmaceuticals is held by insiders.Percentage Held by Institutions72.66% of the stock of Deciphera Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Deciphera Pharmaceuticals are expected to grow in the coming year, from ($2.49) to ($2.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Deciphera Pharmaceuticals is -4.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Deciphera Pharmaceuticals is -4.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDeciphera Pharmaceuticals has a P/B Ratio of 3.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Deciphera Pharmaceuticals (NASDAQ:DCPH) StockDeciphera Pharmaceuticals, Inc. engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.Read More Receive DCPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Deciphera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address DCPH Stock News HeadlinesFebruary 7, 2023 | msn.comDeciphera Pharmaceuticals GAAP EPS of -$0.60 misses by $0.04, revenue of $36.35M beats by $0.47MFebruary 7, 2023 | markets.businessinsider.comSVB Securities Reaffirms Their Buy Rating on Deciphera Pharmaceuticals (DCPH)February 8, 2023 | Wall Street Watch Dogs (Ad)The #1 Energy Stock to BuyThe next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…January 29, 2023 | americanbankingnews.comDeciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Given Average Recommendation of "Moderate Buy" by AnalystsJanuary 25, 2023 | msn.comThe Latest Analyst Ratings for Deciphera PharmaceuticalsJanuary 19, 2023 | markets.businessinsider.comDeciphera Pharma Prices Public Offering Of 6.94 Mln Shares At $18/shrJanuary 19, 2023 | markets.businessinsider.comWhy Deciphera Pharmaceuticals Stock Is NosedivingJanuary 4, 2023 | msn.comDeciphera Pharmaceuticals stock soars 18% as upgraded to Buy at GuggenheimFebruary 8, 2023 | Wall Street Watch Dogs (Ad)The #1 Energy Stock to BuyThe next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…January 4, 2023 | finance.yahoo.comDeciphera's Stomach Cancer Treatment Shows Clinical Benefit In Subgroup Of PatientsJanuary 3, 2023 | finance.yahoo.comDeciphera Pharmaceuticals, Inc. to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 31, 2022 | finance.yahoo.comAre Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 36%?December 14, 2022 | finance.yahoo.comAnalyst Bullish On Theseus Pharma's Platform For Gastric Cancer TherapiesDecember 1, 2022 | finance.yahoo.comDeciphera Pharmaceuticals, Inc. to Present at the JMP Securities Hematology and Oncology SummitNovember 4, 2022 | finance.yahoo.comDeciphera's (DCPH) Q3 Loss Narrows, Qinlock Drives RevenuesNovember 3, 2022 | msn.comDeciphera Pharmaceuticals: Q3 Earnings InsightsNovember 3, 2022 | finance.yahoo.comDeciphera Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial ResultsOctober 27, 2022 | finance.yahoo.comDeciphera Pharmaceuticals, Inc. to Announce Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 3, 2022September 27, 2022 | markets.businessinsider.comWhere Deciphera Pharmaceuticals Stands With AnalystsSeptember 20, 2022 | finance.yahoo.comDeciphera Earns Price Target Bump With Encouraging ESMO PresentationSeptember 14, 2022 | seekingalpha.comDCPH Deciphera Pharmaceuticals, Inc.September 12, 2022 | markets.businessinsider.comSVB Leerink Maintains Outperform Rating for Deciphera Pharmaceuticals: Here's What You Need To KnowSeptember 12, 2022 | nasdaq.comDeciphera Presents Updated Phase 1/2 Data For Vimseltinib In Tenosynovial Giant Cell Tumor AT ESMOSeptember 2, 2022 | nasdaq.comDeciphera Pharmaceuticals (NASDAQ:DCPH) adds US$97m to market cap in the past 7 days, though investors from three years ago are still down 54%August 29, 2022 | markets.businessinsider.com4 Analysts Have This to Say About Deciphera PharmaceuticalsAugust 11, 2022 | finance.yahoo.comDeciphera's Cancer Drug Tops Pfizer's Sutent On Safety Front In Gastrointestinal CancerAugust 10, 2022 | finance.yahoo.comDeciphera Pharmaceuticals (NASDAQ:DCPH) adds US$249m to market cap in the past 7 days, though investors from three years ago are still down 53%See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive DCPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Deciphera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address DCPH Company Calendar Last Earnings11/02/2021Today2/07/2023Next Earnings (Confirmed)2/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DCPH CUSIPN/A CIK1654151 Webwww.deciphera.com Phone(781) 209-6400FaxN/AEmployees280Year FoundedN/APrice Target and Rating Average Stock Price Forecast$22.22 High Stock Price Forecast$30.00 Low Stock Price Forecast$9.00 Forecasted Upside/Downside+32.7%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($3.46) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-299,960,000.00 Net Margins-177.53% Pretax Margin-181.63% Return on Equity-63.88% Return on Assets-48.14% Debt Debt-to-Equity RatioN/A Current Ratio5.58 Quick Ratio5.32 Sales & Book Value Annual Sales$96.15 million Price / Sales11.66 Cash FlowN/A Price / Cash FlowN/A Book Value$5.21 per share Price / Book3.18Miscellaneous Outstanding Shares67,640,000Free Float64,729,000Market Cap$1.12 billion OptionableOptionable Beta0.70 Key ExecutivesSteven L. HoerterPresident & Chief Executive OfficerTucker KellyChief Financial Officer, Treasurer & Executive VPDaniel L. FlynnChief Scientific Officer & Executive VPRodrigo Ruiz SotoSenior Vice President-Clinical DevelopmentStephen B. RuddyChief Technical Officer & SVPKey Competitors23andMeNASDAQ:METaro Pharmaceutical IndustriesNYSE:TAROCassava SciencesNASDAQ:SAVAAclaris TherapeuticsNASDAQ:ACRSLigand PharmaceuticalsNASDAQ:LGNDView All CompetitorsInsiders & InstitutionsTD Asset Management IncSold 5,300 shares on 2/7/2023Ownership: 0.064%State Board of Administration of Florida Retirement SystemSold 5,080 shares on 2/7/2023Ownership: 0.025%ProShare Advisors LLCBought 918 shares on 2/2/2023Ownership: 0.017%SG Americas Securities LLCSold 11,316 shares on 2/2/2023Ownership: 0.014%Zurcher Kantonalbank Zurich Cantonalbank Sold 660 shares on 2/1/2023Ownership: 0.012%View All Insider TransactionsView All Institutional Transactions DCPH Stock - Frequently Asked Questions Should I buy or sell Deciphera Pharmaceuticals stock right now? 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last year. There are currently 1 sell rating, 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DCPH shares. View DCPH analyst ratings or view top-rated stocks. What is Deciphera Pharmaceuticals' stock price forecast for 2023? 9 Wall Street analysts have issued 12 month target prices for Deciphera Pharmaceuticals' stock. Their DCPH share price forecasts range from $9.00 to $30.00. On average, they expect the company's share price to reach $22.22 in the next year. This suggests a possible upside of 34.0% from the stock's current price. View analysts price targets for DCPH or view top-rated stocks among Wall Street analysts. How have DCPH shares performed in 2023? Deciphera Pharmaceuticals' stock was trading at $16.39 at the beginning of the year. Since then, DCPH stock has increased by 1.2% and is now trading at $16.58. View the best growth stocks for 2023 here. When is Deciphera Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 7th 2023. View our DCPH earnings forecast. How were Deciphera Pharmaceuticals' earnings last quarter? Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) posted its quarterly earnings data on Tuesday, November, 2nd. The company reported ($1.37) EPS for the quarter, missing the consensus estimate of ($1.29) by $0.08. The company earned $23.22 million during the quarter, compared to analysts' expectations of $23.73 million. Deciphera Pharmaceuticals had a negative net margin of 177.53% and a negative trailing twelve-month return on equity of 63.88%. During the same period in the prior year, the firm posted ($1.13) earnings per share. What guidance has Deciphera Pharmaceuticals issued on next quarter's earnings? Deciphera Pharmaceuticals updated its fourth quarter 2022 earnings guidance on Tuesday, January, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $36.00 million-$36.00 million, compared to the consensus revenue estimate of $34.83 million. What is Steve Hoerter's approval rating as Deciphera Pharmaceuticals' CEO? 3 employees have rated Deciphera Pharmaceuticals Chief Executive Officer Steve Hoerter on Glassdoor.com. Steve Hoerter has an approval rating of 100% among the company's employees. This puts Steve Hoerter in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Deciphera Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include NVIDIA (NVDA), Ionis Pharmaceuticals (IONS), Vertex Pharmaceuticals (VRTX), Allena Pharmaceuticals (ALNA), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Iovance Biotherapeutics (IOVA), SCYNEXIS (SCYX), Axsome Therapeutics (AXSM) and Exelixis (EXEL). When did Deciphera Pharmaceuticals IPO? (DCPH) raised $101 million in an initial public offering on Thursday, September 28th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO and JMP Securities and Nomura were co-managers. What is Deciphera Pharmaceuticals' stock symbol? Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH." Who are Deciphera Pharmaceuticals' major shareholders? Deciphera Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (1.50%), Allspring Global Investments Holdings LLC (0.14%), Hennion & Walsh Asset Management Inc. (0.10%), TD Asset Management Inc (0.06%), Inspire Investing LLC (0.02%) and ProShare Advisors LLC (0.02%). Insiders that own company stock include Brightstar Associates Llc, Daniel Lee Flynn, Jama Pitman, James Arthur Bristol, Matthew L Sherman, Michael Douglas Taylor, Patricia L Allen and Thomas Patrick Kelly. View institutional ownership trends. How do I buy shares of Deciphera Pharmaceuticals? Shares of DCPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Deciphera Pharmaceuticals' stock price today? One share of DCPH stock can currently be purchased for approximately $16.58. How much money does Deciphera Pharmaceuticals make? Deciphera Pharmaceuticals (NASDAQ:DCPH) has a market capitalization of $1.12 billion and generates $96.15 million in revenue each year. The company earns $-299,960,000.00 in net income (profit) each year or ($3.46) on an earnings per share basis. How many employees does Deciphera Pharmaceuticals have? The company employs 280 workers across the globe. How can I contact Deciphera Pharmaceuticals? Deciphera Pharmaceuticals' mailing address is 200 SMITH STREET, Waltham MA, 02451. The official website for the company is www.deciphera.com. The company can be reached via phone at (781) 209-6400 or via email at eciphera@argotpartners.com. This page (NASDAQ:DCPH) was last updated on 2/8/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.